Internal Medicine, Infectious Disease · Fort Worth, TX
NPI
1275533846
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
1307 8th Avenue, Suite 306
Fort Worth, TX, 76104
Phone (817) 921-0123
Groups this clinician bills Medicare through
Medicare paid, 2024
$35K
544 services
Medicare patients, 2024
119
Average age 72
Drug cost, 2024
$3.8M
2,576 prescriptions
Company payments, 2025
$121
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Catherine A Colquitt was code 99232 (hospital e&m - subsequent), 312 times for 43 patients. In total Catherine A Colquitt billed 544 services in 26 codes, and Medicare paid $35K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 312 | 43 | $60.95 | $19K |
| 99213 Office E&M - Established | Office | 90 | 54 | $54.48 | $4,903 |
| 99222 Hospital E&M - Initial | Facility | 40 | 33 | $100.99 | $4,040 |
| G0008 Administration of influenza virus vaccine | Office | 18 | 18 | $31.92 | $575 |
| 90480 Vaccine Administration | Office | 13 | 13 | $37.69 | $490 |
| 91320 Vaccine Product | Office | 12 | 11 | $125.87 | $1,510 |
By year: 2022 $57K for 1,049 services; 2023 $46K for 775 services; 2024 $35K for 544 services.
Medicare prescription drug claims, 2024
In 2024, the drug Catherine A Colquitt prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 258 prescriptions and refills. In total Catherine A Colquitt wrote 2,576 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 258 | 260 | 32 | $1.0M |
| Tivicay Dolutegravir Sodium | 152 | 152 | 18 | $478K |
| Azithromycin Generic | 151 | 151 | 131 | $519 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 142 | 150 | 17 | $595K |
| Dovato Dolutegravir Sodium/Lamivudine | 124 | 124 | 14 | $352K |
| Prezcobix Darunavir/Cobicistat | 99 | 99 | 11 | $251K |
| Rosuvastatin Calcium Generic | 94 | 122 | 13 | $494 |
| Valacyclovir Valacyclovir Hcl | 81 | 90 | 12 | $1,940 |
| Juluca Dolutegravir/Rilpivirine | 76 | 76 | 11 | $259K |
| Ritonavir Generic | 69 | 71 | Under 11 | $4,174 |
| Darunavir Generic | 59 | 59 | Under 11 | $56K |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 51 | 51 | Under 11 | $188K |
| Edurant Rilpivirine Hcl | 47 | 47 | Under 11 | $66K |
| Atovaquone-Proguanil Hcl Atovaquone/Proguanil Hcl | 43 | 44 | 43 | $2,476 |
| Amlodipine Besylate Generic | 43 | 73 | Under 11 | $114 |
Brand drugs: 1,116 claims; generic drugs: 1,460 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Catherine A Colquitt $121 ($121 in general payments such as food, travel and fees) from 4 companies. The largest payer was Pfizer Inc. with $44.85.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.